Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow (FCF).

1177 Free Cash Flow Analysis

Free cash flow, a measure commonly used by analysts to assess a company's profitability, represents the cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

The Free Cash Flow is calculated using a number of methods including using Operating Cash Flow. Following is the formula to calculate Free Cash Flow based on Operating Cash Flow.

Free Cash Flow = Operating Cash Flow - Capital Expenditures

Using above formula to calculate Free Cash Flow for Sino Biopharmaceutical Limited (1177), the free cash flow value is 3.652163B.

All amounts in CNY

Operating Cash
5.37B
Capital Expenditure
-1.71B
Free Cash Flow
3.652163B

Sino Biopharmaceutical Limited has a positive free cash flow as per the latest annual Cash flow statement released by the company. Positive free cash flow is cruscial for the financial health of a company, which can be used to pay dividends, expand operations, and deleverage its balance sheet (i.e., reduce debt).

1177 Cash Flow Statement History

Following table shows the history of Cash Flow Statements sheet for Sino Biopharmaceutical Limited (HKEX:1177).

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Net Income14.61B2.77B2.76B9.05B
Depreciation922.74M1.64B1.4B1.16B
Change To Netincome-9.96B568.8M1.36B-5.42B
Change To Account Receivables-1.31B-198.79M196.31M-436.21M
Change To Liabilities-191.59M334.05M-143.2M870.48M
Change To Inventory-57.48M-221.45M-449.44M-102.16M
Change To Operating Activities1.22B347.52M113.52M-88.81M
Total Cash From Operating Activities5.37B5.33B5.32B5.09B
Capital Expenditures-1.71B-1.42B-1.45B-1.55B
Investments-4.39B-6.54B-2.45B-668.25M
Other Cashflows From Investing Activities4.41B383.13M343.89M510.46M
Total Cashflows From Investing Activities-2.52B-7.85B-3.82B-616.1M
Dividends Paid-938.49M-1.19B-819.69M-710.33M
Net Borrowings-1.5B5.34B5.17B304.67M
Other Cashflows From Financing Activities-452.37M-1.72B-1.51B-1.17B
Total Cash From Financing Activities-3.23B2.23B2.8B-2.18B
Effect Of Exchange Rate-649.71M280.01M95.05M242.47M
Change In Cash-1.02B-7.02M4.4B2.54B
Repurchase Of Stock-332.93M-195.37M-32.05M-604.42M